Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03189706
Title Study of Chemoimmunotherapy for High-Risk Neuroblastoma
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Memorial Sloan Kettering Cancer Center
Indications

neuroblastoma

Therapies

Irinotecan + Naxitamab + Sargramostim + Temozolomide

Age Groups: adult | child | senior
Covered Countries USA


No variant requirements are available.